Back to dashboard
CommercialCoverageMedium impact

Management of Dry Eye Syndrome and Meibomian Gland Dysfunction (e.g., LipiFlow) 9.01.19

Excellus BlueCross BlueShield·Ophthalmology·Eyes (Ophthalmology)
Effective date
Dec 18, 2025
We identified it
Jun 20, 2026
Days to comply

Summary

Excellus BlueCross BlueShield has classified several dry eye syndrome treatments as investigational and non-covered, including eyelid thermal pulsation therapy (LipiFlow, iLux System, TearCare, Tixel i) and tear film imaging devices (LipiView, LipiScan). These procedures will not be reimbursed by this payer.

Action Required

Action needed
By December 18, 2025: Billing team must update system to flag dry eye thermal pulsation treatments (LipiFlow, iLux, TearCare, Tixel i) and tear film imaging (LipiView, LipiScan) as non-covered for Excellus BlueCross BlueShield patients. Update encounter forms to alert ophthalmology providers that these services are considered investigational. Obtain advance beneficiary notices (ABNs) if patients want to proceed with treatment at their own expense.